Longevity & AgingEnhanced MRI Detects Liver Cancer Far Earlier Than Ultrasound in High-Risk Patients
A randomized clinical trial comparing screening tools for liver cancer found that an enhanced, abbreviated MRI using a contrast agent called gadoxetic acid dramatically outperformed standard ultrasound in detecting early-stage hepatocellular carcinoma (HCC) in high-risk patients with cirrhosis. Among 759 patients, the MRI approach detected early-stage cancer in 7.7% of patients versus just 2.9% with ultrasound. Even very early-stage cancers were caught at a rate of 6.1% with MRI compared to only 0.8% with ultrasound. As a bonus, MRI also produced fewer false referrals — unnecessary follow-up procedures triggered by suspicious but non-cancerous findings. These results, presented at a major liver disease conference, suggest that upgrading surveillance protocols for high-risk individuals could meaningfully improve survival outcomes.
